AP Biosciences Inc (6945.TWO)
TWD 49.6
(0.51%)
TWD 49.6
(0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 32.25 Million | - | 6.99 Million | 137.56 Thousand |
| Cost of Revenue | - | - | - | - |
| Gross Profit | 32.25 Million | - | 6.99 Million | 137.56 Thousand |
| Operating Expenses | 32.25 Million | 297.49 Million | 193.71 Million | 92.54 Thousand |
| Selling, General and Administrative Expenses | 43.13 Million | 34.81 Million | 19.9 Million | - |
| Research and Development Expenses | 336.6 Million | 262.67 Million | 173.81 Million | 67.35 Thousand |
| Other Expenses | - | 6.37 Million | -1.1 Million | -3542.00 |
| Cost and Expenses | 379.73 Million | 297.49 Million | 193.71 Million | 92.54 Thousand |
| Operating Income | -347.47 Million | -288.53 Million | -186.71 Thousand | -45.01 Thousand |
| Interest Expense | 1.2 Million | - | - | - |
| Income Tax Expense | - | - | -186.53 Million | 90.03 Thousand |
| Earnings before Tax | -339.29 Million | -288.53 Million | -187.6 Million | 41.74 Thousand |
| Net Income | -339.29 Million | -288.53 Million | -187.6 Million | 41.74 Thousand |
| Earnings Per Share Basic | -5.24 | -5.48 | -3.89 | 0.01 |
| Earnings Per Share Diluted | -5.24 | -5.48 | -3.89 | 0.01 |
| Weighted Average Shares Outstanding | 64.74 Million | 52.64 Million | 48.23 Million | 6.47 Million |
| Weighted Average Shares Outstanding (Diluted) | 64.74 Million | 52.64 Million | 48.23 Million | 6.47 Million |
| Gross Margin | 1.00 | - | 1.00 | 1.00 |
| EBIT Margin | -10.09 | - | -25.43 | 0.38 |
| Profit Margin | -10.52 | - | -26.83 | 0.30 |
| EBITDA | -325.51 Million | -290.07 Million | -177.85 Million | 52.21 Thousand |
| Earnings Before Tax Margin | -10.77 | - | -0.03 | -0.33 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 16.12 Million | 32.25 Million | 16.12 Million | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | 16.12 Million | 32.25 Million | 16.12 Million | - |
| Operating Expenses | 116.68 Million | 114.34 Million | 128.99 Million | 379.73 Million | 128.99 Million | 61.19 Million |
| Selling, General and Administrative Expenses | 16.5 Million | 16.5 Million | 12.32 Million | - | 12.32 Million | 9.23 Million |
| Research and Development Expenses | 100.18 Million | 100.18 Million | 115.05 Million | - | 115.05 Million | 53.24 Million |
| Other Expenses | 1.00 | - | - | -642 Thousand | - | - |
| Cost and Expenses | 116.68 Million | 114.34 Million | 128.99 Million | 379.73 Million | 128.99 Million | 61.19 Million |
| Operating Income | -116.68 Million | -116.68 Million | -111.25 Million | -338.09 Million | -111.25 Million | -62.48 Million |
| Interest Expense | - | - | - | 1.2 Million | - | - |
| Income Tax Expense | - | - | - | - | - | - |
| Earnings before Tax | -113.13 Million | -113.13 Million | -110.6 Million | -339.29 Million | -110.6 Million | -59.04 Million |
| Net Income | -113.13 Million | -113.13 Million | -110.6 Million | -339.29 Million | -110.6 Million | -59.04 Million |
| Earnings Per Share Basic | -1.72 | -1.73 | -1.71 | - | -1.71 | -0.91 |
| Earnings Per Share Diluted | -1.72 | -1.73 | -1.71 | - | -1.71 | -0.91 |
| Weighted Average Shares Outstanding | 65.58 Million | 65.58 Million | 64.74 Million | 64.74 Million | 64.74 Million | 64.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 65.58 Million | 65.58 Million | 64.74 Million | 64.74 Million | 64.74 Million | 64.74 Million |
| Gross Margin | - | - | 1.00 | 1.00 | 1.00 | - |
| EBIT Margin | - | - | -6.59 | - | -6.59 | - |
| Profit Margin | - | - | -6.86 | -10.52 | -6.86 | - |
| EBITDA | -115.76 Million | -112.65 Million | -106.22 Million | - | -106.22 Million | -61.71 Million |
| Earnings Before Tax Margin | - | - | -6.90 | -10.48 | -6.90 | - |
6083
6899
2493
4295
688329
005257